Long-term treatment with low doses of interleukin-2 and interferon-α: immunological effects in advanced renal cell cancer

2001 ◽  
Vol 50 (2) ◽  
pp. 82-86 ◽  
Author(s):  
Laura Pavone ◽  
Simeone Andrulli ◽  
Rosaria Santi ◽  
Maria Majori ◽  
Carlo Buzio
Keyword(s):  
Renal Cell ◽  
Cell Cancer ◽  
Interleukin 2 ◽  
Term Treatment ◽  
Interferon Α ◽  
Low Doses ◽  
Long Term Treatment ◽  
Immunological Effects ◽  
Advanced Renal Cell Cancer

scholarly journals Sunitinib treatment promotes metastasis of drug-resistant renal cell carcinoma via TFE3 signaling pathway

2021 ◽  
Vol 12 (2) ◽  
Author(s):  
Luchao Li ◽  
Shuo Zhao ◽  
Zhengfang Liu ◽  
Nianzhao Zhang ◽  
Shuo Pang ◽  
...  
Keyword(s):  
Renal Cell ◽  
Cell Cancer ◽  
Acquired Resistance ◽  
Resistant Cell ◽  
Term Treatment ◽  
Acquired Drug Resistance ◽  
Sunitinib Treatment ◽  
Long Term Treatment

AbstractReceptor tyrosine kinase (RTK) inhibitors, such as sunitinib and sorafenib, remain the first-line drugs for the treatment of mRCC. Acquired drug resistance and metastasis are the main causes of treatment failure. However, in the case of metastasis Renal Cell Cancer (mRCC), which showed a good response to sunitinib, we found that long-term treatment with sunitinib could promote lysosome biosynthesis and exocytosis, thereby triggering the metastasis of RCC. By constructing sunitinib-resistant cell lines in vivo, we confirmed that TFE3 plays a key role in the acquired resistance to sunitinib in RCC. Under the stimulation of sunitinib, TFE3 continued to enter the nucleus, promoting the expression of endoplasmic reticulum (ER) protein E-Syt1. E-Syt1 and the lysosomal membrane protein Syt7 form a heterodimer, which induces ER fragmentation, Ca2+ release, and lysosomal exocytosis. Lysosomal exocytosis has two functions: pumping sunitinib out from the cytoplasm, which promotes resistance to sunitinib in RCC, releasing cathepsin B (CTSB) into the extracellular matrix (ECM), which can degrade the ECM to enhance the invasion and metastasis ability of RCC. Our study found that although sunitinib is an effective drug for the treatment of mRCC, once RCC has acquired resistance to sunitinib, sunitinib treatment will promote metastasis.

Immunotherapy of advanced renal cell cancer using subcutaneous recombinant interleukin-2 and interferon-α

1991 ◽  
Vol 9 (4) ◽  
pp. 219-222 ◽  
Author(s):  
H. Kirchner ◽  
W. de Riese ◽  
E. Allhoff ◽  
H. Poliwoda ◽  
J. Atzpodien
Keyword(s):  
Renal Cell Cancer ◽  
Renal Cell ◽  
Cell Cancer ◽  
Interleukin 2 ◽  
Interferon Α ◽  
Recombinant Interleukin 2 ◽  
Advanced Renal Cell Cancer

scholarly journals Treatment of metastatic renal cell cancer patients with recombinant subcutaneous human interleukin-2 and interferon-α

1990 ◽  
Vol 1 (5) ◽  
pp. 377-378 ◽  
Author(s):  
J. Atzpodien ◽  
A. Körfer ◽  
P.A. Palmer ◽  
C.R. Franks ◽  
H. Poliwoda ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Renal Cell Cancer ◽  
Renal Cell ◽  
Cell Cancer ◽  
Interleukin 2 ◽  
Interferon Α ◽  
Metastatic Renal Cell Cancer
Sign in / Sign up

Export Citation Format

Share Document